Skip to main content

Advertisement

Table 1 Demographic details, treatment outcomes based on virologic responses, viral load at baseline and serial serum samples analysed over time for HCV genotype 3a chronically infected patients

From: Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a

Patient Group Type of Response Sex Rx Naïve Age (years) at Baseline Viral Load log10 IU/ml at Baseline Time points
       Pre treatment period Early treatment period Post treatment period
Sustained virological response (SVR)    Mean Age 41 ± 12 Mean VL 5.66 ± 0.66 E B W1 W2 W3 W4 L
SVR3 SVR F Yes 28 5.47 + + + + + - (V) TND
SVR6 SVR F Yes 35 5.16 + + - (V) TND TND TND TND
SVR7 SVR F Yes 32 5.46 + + + - (V) TND TND TND
SVR8 SVR F Yes 59 6.89 + + + NA NA + (V) TND
SVR9 SVR F No 45 6.37 + + + + NA - (V) TND
SVR12 SFR F Yes 49 5.17 + + TND TND TND TND TND
Treatment failure (TF)    Mean Age 41 ± 7 Mean VL 6.23 ± 0.63 E B W1 W2 W4 W12* L
NR2 NR F Yes 42 5.05 + + + NA + + + (W3)
R1 R M Yes 46 7.5 + + + (V) TND TND TND + (W2)
R4 R M Yes 45 7.11 + + + + (V) TND TND + (W10)
R13 R M Yes 31 6.32 + + + - TND TND - (W12)
  1. The pre treatment period corresponds to E and B time point. E for early sample, taken between 6 to 12 months before treatment and B for baseline sample, taken at day 0 of pegylated INF-α2a/ribavirin treatment. The early treatment period corresponds to W1 to W4 time points (samples taken at 1, 2, 3 or 4 weeks of treatment). The sample taken at week 12 of treatment was only available for the non-responder patient (W12*). The post treatment period corresponds to the L time point and was only available within the TF group. L for late sample taken at 2, 3, 10 or 12 weeks after the end of treatment). +, sample available with successful analysis. -, sample available with unsuccessful analysis. TND, target not detected when HCV RNA was not detectable in the sample. (V), sample treated with the Viraffinity™ reagent. NA, sample non available for analysis.